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Effect of serum subfractions from peritoneal dialysis patients on
Hep-G2 cell apolipoprotein A-I and B metabolism. We previously showed
that uremic serum subfractions isolated from hemodialysis (HD) patients
inhibited the production of apolipoprotein (apo) A-I by human hepato-
blastoma cells, Hep-G2. Because of the reported differences in athero-
genie cardiovascular mortality between HD and peritoneal dialysis (PD)
patients, we examined the effect of similar subfractions from PD patients
on apo A-I and apo B synthesis. After obtaining informed consent, serum
samples from five normal subjects and nine stable PD patients were
applied to Sephadex G-25 columns to obtain the serum subfractions used
in the various experiments. Sephadex G-25 chromatograms of PD sera
showed a broad peak from fractions 30 through 60 (molecular wt 500 to
2000 Da). Control serum showed no peak in this region. PD serum
suhfractions decreased apo A-I synthesis, secretion, and apo A-I mRNA
expression by Hep-G2 cells when compared to subfractions from control
subjects. Cholesterol efflux studies showed that conditioned media ob-
tained from Hep-G2 cells incubated with PD serum subfractions inhibited
cholesterol cifiux from fibroblasts, suggesting a biologically-significant
decrease in apo A-I synthesis. PD serum subfraetions increased protein
synthesis and mRNA expression of apo B by Hep-G2 cells. Therefore,
serum subfractions obtained from PD patients decreased apo A-I and
increased apo B synthesis, findings consistent with their serum lipoprotein
profiles suggesting that a biologically-active component in these subfrac-
tions could contribute to the risk of atherogenie cardiovascular disease in
PD.
Atherosclerotic cardiovascular disease is the most frequent
cause of morbidity and mortality in patients with end-stage renal
disease (ESRD) receiving dialytic therapy. Recent epidemiologi-
cal data from the U.S. Renal Data System showed that peritoneal
dialysis (PD) was associated with a 19% higher all-cause mortality
when compared to hemodialysis (HD) and that cardiovascular
disease accounted for 40% of the observed differences in mortal-
ity between the two groups [1, 21. Although the reasons for these
observations have not been fully explained, considerable efforts
have been made to identify the potential factors that enhance the
development of atherosclerotic cardiovascular disease in both PD
and HD patients. Generally, abnormalities in lipid and lipoprotein
metabolism are associated with a greater risk of cardiovascular
disease, and the correction of these abnormalities has been shown
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to have beneficial effects. Since patients receiving maintenance
dialysis therapy often have abnormal serum lipid and lipoprotein
profiles [3, 4], it has been proposed that lipid abnormalities in
these patients may contribute to the cardiovascular mortality in
ESRD patients as compared to other populations of patients
without renal disease.
Interestingly, the pattern of lipid and lipoprotein abnormalities
seen in PD patients is different from that seen in patients
undergoing HD. Studies have shown that both HD and PD
patients have elevated levels of serum triglycerides (TG) and
decreased levels of HDL-eholesterol (HDL-C) [5, 61. In addition,
PD patients often show elevated levels of LDL-cholesterol
(LDL-C) as compared to HD patients in whom LDL-C is often
normal [5, 61. Serum levels of other lipoproteins purported to
increase the risk of atherosclerotic cardiovascular disease includ-
ing lipoprotein (a) is also increased [7, 81 in both uremie patients
and those receiving either HD or PD treatment. Consistent with
the abnormalities in circulating lipid and lipoproteins seen in
patients undergoing PD, serum apolipoprotein (apo) measure-
ments demonstrated decreased A-I and elevated apo B concen-
trations [6, 7] associated with the decreased HDL-C and elevated
LDL-C levels in the circulation. Hence, although it has not been
clearly established, it seemed reasonable to speculate that uremic
dyslipidemia may enhance the risk for the development of ath-
erosclerotic cardiovascular disease in ESRD patients, and that the
specific lipid and lipoprotein abnormalities seen in patients un-
dergoing PD may result in a greater risk of developing athero-
genie cardiovascular disease in these patients when compared to
those undergoing HD.
Several factors may influence the dyslipidemia observed in PD
patients including continuous peritoneal glucose loading, hy-
poalbuminemia, the administration of various pharmacological
agents, and coexisting medical conditions including diabetes mel-
litus and hypertension. In addition, peritoneal apo losses and the
metabolic effects of uremic toxins may contribute to some of the
abnormal lipid metabolism noted in ESRD patients. In a previous
study, we have shown that serum subfractions isolated from
patients receiving hemodialysis therapy inhibited both the synthe-
sis and secretion of apo A-I by Hep-G2 cells, a human hepatoma
cell line [9]. In view of the differences in lipoprotein metabolism
between HD and PD patients, and the increased frequency of
atherosclerotic cardiovascular disease in PD patients, we hypoth-
esized that patients undergoing PD treatment may be exposed to
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additional atherogenic factors because of differences in perme-
ability and clearance characteristics between the HD and PD
membranes [10]. In this regard, since apo B associated with LDL
is consistently shown to be elevated in PD patients in addition to
decreased serum apo A-I and HDL-C, we examined the ability of
subfractions obtained from stable patients undergoing PD on the
protein synthesis and gene expression of apo B and apo A-I by
Hep-G2 cells. Furthermore, we examined the biological activity of
the apo A-I produced by Hep-G2 cells after exposure to uremic
subfraction obtained from patients undergoing PD to determine
the ability of apo A-I to efflux cholesterol from human fibroblasts.
Methods
All tissue culture materials and media including fetal bovine
serum (FBS) were obtained from Sigma Chemical Company (St.
Louis, MO, USA). L-[4,5-3H]leucine was purchased from Amer-
sham Corporation (Arlington Heights, IL, USA). Sephadex G-25
was purchased from Pharmacia Fine Chemicals (Piscataway, NJ,
USA). A polyclonal antibody for human apo A-I was obtained
from Medix Biotech Inc. (Foster City, CA, USA) and an antibody
for apo B from Boehringer Mannheim Corporation (Indianapolis,
IN, USA). Human hepatocellular carcinoma cells, Hep-G2, and
human apo A-I and B eDNA probes were obtained from Amer-
ican Type Culture Collection (Rockville, MD, USA). All other
chemicals used were of analytical grade.
Patients and control subjects
Nine male patients receiving continuous ambulatory peritoneal
dialysis (PD) and five healthy male volunteers were studied. The
duration of dialysis ranged from six months to 12 years. Clinical
diagnoses in the ESRD patients included arteriolar nephroscle-
rosis (4), diabetic nephropathy (2), polycystic kidney disease (1),
reflux nephropathy (1), and unknown (1). After obtaining in-
formed consent, fasting venous blood samples were drawn. The
patients were instructed not to eat and not to perform any dialysis
exchanges on the night before blood sample collection to avoid
glucose loading and achieve a true fasting state. Serum, drawn
from a peripheral vein, was separated by centrifugation and either
used immediately or stored at —70°C before subfraction isolation.
Patients were excluded from the study if they had unstable
diabetes mellitus, nephrotic range proteinuria, obesity or were
receiving specific treatments including certain medications such as
/3-adrenergic blocking drugs, diuretics, corticosteroids, androgens,
lipid-lowering drugs, erythropoietin [11], or were ingesting a
modified fat diet known to influence lipoprotein metabolism.
None of the patients were cigarette smokers for the previous 12
months. Serum lipid profiles and apo A-I and apo B levels were
determined by methods previously described [9].
Isolation of uremic serum subfractions
Uremic serum subfractions were isolated as previously de-
scribed [9]. Briefly, serum samples (2 ml) were applied to Seph-
adex G-25 columns (16 X 75 mm) and eluted using phosphate-
buffered saline (PBS) at a flow rate of 0.6 mi/mm. The void
volume of the column was approximately 40 ml. Four minute
subfractions were collected and the absorbance at 280 nm of each
subfraction was measured. Subfractions 30 to 60 were pooled,
lyophilized and reconstituted in 10 ml of PBS and used as uremic
serum subfractions in experimental incubations with Hep-G2
cells. The reconstituted serum subfractions were diluted with
culture medium 10 times prior to use.
Cell culture
A human hepatoblastoma cell line, Hep-G2, was grown in T-75
flasks with 15 ml of high glucose Dulbecco's modified Eagles
medium (DMEM) containing 10% FBS, 1% glutamine-penicillin-
streptomycin and 1% fungizone. Cells were grown in a humidified
incubator at 37°C in an atmosphere of 5% CO2 and 95% air.
Subcultures were made from confluent stock cultures by
trypsinization in PBS containing 0.5 m ethylene diamine tet-
raacetic acid.
Studies on secretion of apo A-I
Hep-G2 cells were plated in 60 mm culture petri dishes at a
concentration of 2 x 106 cells/dish in 3 ml of DMEM and grown
for three to four days until they attained 75 to 80% confluence.
The studies examining the dose response of uremic serum sub-
fractions on apo A-I secretion were performed by incubating
Hep-G2 cells with two concentrations of the normal or uremic
serum subfractions (100 and 200 jtl) at 37°C for 72 hours. At the
termination of the incubation, culture media from each flask was
removed, the cell monolayers washed with PBS, and digested with
1 ml of 1 N NaOH for protein measurement [12]. A 50 p1 sample
of culture media was assayed for apo A-I by an enzyme-linked
immunosorbent assay [13] using an apo A-I specific monoclonal
antibody developed and characterized in the Cholesterol Center
Lipid Laboratory at this Medical Center [13]. This monoclonal
antibody against human apo A-I showed no cross reactivity with
human apo A-lI, LDL, VLDL, or albumin, or to bovine apo A-I.
The concentration of apo A-I was expressed as sg per mg of
cellular protein. The enzyme-linked immunosorbent assay utilized
was linear over a concentration range of 0.5 to 50 jLg/ml with a
correlation coefficient = 0.995. The aliquots of media used in the
assays performed for this study corresponded to a concentration
of 2 to 30 ig/ml, values within the linear range of the assay.
Pooled normal human plasma served as a source for the apo A-I
standard that was calibrated against the CDC-reference plasma by
a CDC-lipid/apolipoprotein standardization.
De novo synthesis of apo A-I and apo B
Studies examining the effect of various doses of the normal or
uremic serum subfraction on apo A-I and B synthesis by I-Jep-G2
were performed as described in secretion studies except that these
incubations contained 5 sCi/ml of L-[4,5-3H]leucine. The de novo
synthesis of apo were performed by measuring the incorporation
of radiolabeled leucine into apo A-I or apo B secreted into the
media [14]. In brief, 100 pA of the medium was added to an
Eppendorif tube containing 200 uI PBS and 100 pi of antihuman
apo A-I or B (1:50 dilution). The polyclonal anti-apo A-I did not
cross react with human LDL, VLDL, albumin, or with FBS as
determined by an immunodiffusion method. Similarly, human
anti-apo B used was specific for apo B but not for apo A-I or other
apolipoproteins. After a 48 hour incubation at 4°C, 100 pA of
rabbit IgG (1:10 dilution) was added to each tube and incubated
for 24 hours at 4°C. The precipitated apo A-I or apo B immune
complexes were separated by centrifugation, the pellets washed 5
times with PBS containing 0.1% sodium dodecyl sulfate, dissolved
in 500 u' of0.5 N NaOH, and a 400 pi aliquot was used to measure
the radioactivity. The incorporation of [3H]leucine into apo A-I or
apo B was expressed as cpm/mg cellular protein. To validate the
specificity of the immunoprecipitation technique, the immuno-
complex of apo A-I was dissolved in SDS-PAGE sample buffer
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and electrophoresed. All the radioactivity on SDS-PAGE gel was
present in a band corresponding to apo A-I (28 kDa) but not in
the range of apo A-Il or other proteins. Similar analysis for apo B
immunocomplex was also performed and all of the radioactivity
was noted in apo B band. Therefore, these data validate the
specificity of immunoprecipitation technique using monospecific
antibodies to measure synthesis of apolipoproteins.
Measurement of cholesterol efflux
Experimental protocols for these studies were identical to those
described for the secretion of apo A-I. After the incubation of
Hep-G2 cells with serum subfractions, the media was collected
and used for cholesterol efflux measurement. An aliquot of media
(5 ml) was concentrated to 1 ml by lyophilization and dialyzed
against DMEM to remove excess salt present in the concentrated
sample. The ability of these concentrated samples to efflux free
cholesterol was measured by a previously described procedure of
Fielding and Fielding [151 and Rothblatt, Bamberger and Phillips
[16] utilizing [3Hlcholesterol-labeled human fibroblasts. To en-
sure specific and homogenous incorporation of radiolabeled
cholesterol throughout the cytoplasmic matrix of fibroblasts, we
incubated fibroblasts with 3H-cholesterol for 72 hours, washed
with PBS and then incubated with fresh DMEM media containing
1% fetal bovine albumin for 16 hours at 37°C. Cholesterol efflux
assay was initiated by incubating concentrated culture media with
[3H]cholesterol-labeled fibroblasts for 20 hours in a humidified
incubator. Quantitative analysis of the ability of culture media (in
the presence or absence of serum subfractions) was assessed by
measuring the radioactivity appearing into the medium per ml of
incubation medium.
Northern blot analysis
Hep-G2 cells were incubated with various aliquots of normal or
uremic serum subfractions for 72 hours at 37°C. After incubation,
the media was removed and cell monolayers washed three times
with PBS. Total RNA was isolated from Hep-G2 cells using the
protocol of Chomczynski and Sacchi [17]. In brief, Hep-G2 cells
were homogenized with 4 M guanidinium thiocyanate, total pro-
tein and DNA were extracted with acid phenol and the RNA
precipitated using isopropanol. After washing with ethanol, the
samples were dried under vacuum centrifugation and the amount
of RNA was quantitated spectrophotometrically by measuring the
absorbance at 260 nm. Twenty micrograms of total RNA were
loaded into individual wells of a 1.2% agarose gel containing
formaldehyde and electrophoresis performed [18]. The RNA
from the gel was transferred onto MSI nylon membranes (Fisher
Scientific, Pittsburgh, PA, USA) using a capillary transfer tech-
nique. The nylon membrane was UV-linked using a UV-
Crosslinker (Fisher Scientific). The membrane was hybridized
with [32P]-labeled human apo A-I or apo B eDNA probes using
random hexanucleotide primers. The membranes were washed
three times for 30 minutes: first, in 2 x SSC with 0.1% SDS at
25°C; second, in 0.5 >< SSC with 0.1% SDS at 25°C; and third, in
0.5 x SSC with 0.1% SDS at 55°C. Autoradiography was per-
formed by exposing the blots to Kodak X-ray film with intensifying
screens at —70°C. Blots were then rehybridized with human
[32P]glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Clon-
tech, Palo Alto, CA, USA) probe as an internal standard to assess
RNA quantity and integrity. Quantitative analysis of the apo A-I
and apo B mRNA message was performed by densitometric
scanning of the blots and normalizing with their respective
GAPDH message.
Statistical analysis
Data presented are the mean SE of three separate experi-
ments. All incubations were performed in triplicate. Statistical
significance was calculated by using the Student's t-test for
unpaired data or analysis of variance when appropriate.
Results
Serum lipid profiles of the PD patients showed the following
values: total cholesterol 230 24 mg/dl, LDL-C 153 20 mg/dl,
HDL-C 36 3 mg/dl, and TG 206 30 mgldl. Serum apo A-I
level were 134 7 mgldl (reference range 94 to 178 mg/dl) and
apo B concentrations were 135 18 mgldl (reference range 52 to
109 mg/dl). The serum albumin levels were 3.7 0.1 g/dl. Based
on the kinetic modeling, the values of normalized protein cata-
bolic rate (NPCR), weekly Kt/V and creatinine clearance were
0.8 0.1 g!kg!day, 1.9 0.5 and 67 7 liter/1.73 m2/day,
respectively.
Figure 1A shows Sephadex G-25 chromatographic profiles of
sera from a representative uremic patient undergoing PD and a
representative control subject. A broad peak from fractions 30
through 60 was observed in all nine PD patients, but not in any of
the control subjects. Based on the use of calibrator molecular
weight markers, the molecular weights of the components of this
fraction were between 500 and 2000 Da, and were similar to that
previously reported by us and others who have isolated subfrac-
tions from uremic serum [9, 19, 20]. Figure lB shows the optical
densities measured in the 30 to 60 fractions of a representative
normal subject and in five PD patients. Despite some variability in
the results, all of the PD patients showed an increased accumu-
lation of optically-dense material when scanned at a 280 nm
wavelength as compared to the control subjects.
Apo A-I studies
The incubation of various quantities of the uremic serum
subfractions for 72 hours with Hep-G2 cells showed a dose-
dependent decrease in apo A-I accumulation in the media as
measured by an enzyme-linked immunosorbent assay. As seen in
Figure 2, a 15% decrease in Hep-G2 cell apo A-I accumulation in
the media was noted at 100 pA of the uremic serum subfraction
(P < 0.05 vs. control), and the maximum decline in apo A-I in the
media (42%) was observed at 200 pA of the subfraction (P < 0.001
vs. control). Incubation of Hep-G2 cells with uremic serum
subfractions at these doses for 72 hours did not alter the mor-
phology by light microscopy or the viability of cells as assessed by
trypan blue exclusion criteria. At these doses (100 to 200 j.tl),
addition of a similar subfraction obtained from normal subject
serum did not show any changes in apo A-I secretion by Hep-G2
cells when compared to a PBS control.
Experiments were designed to examine the de novo biosynthesis
of apo A-I by measuring the incorporation of [3Hlleucine into
newly synthesized apo A-I secreted into the media. The effect of
time of incubation on apo A-I synthesis by Hep-G2 cells in the
presence of 200 rl of serum subfractions was examined. The
results indicated that the incubation of Hep-G2 cells with uremic
subfractions for 24 hours did not alter the synthesis of apo A-I
(Fig. 3A). At 48 hours, uremic subfractions decreased apo A-I
synthesis, with a maximal effect seen at 72 hours of incubation.
The data in Figure 3B show that when Hep-G2 cells were
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incubated with the uremic serum subfractions (100 and 200 pl),
the incorporation of radiolabeled leucirie into newly synthesized
apo A-I by these cells decreased by more than 50% when
compared to the normal sera (P < 0.00 1). Twenty-five and 50 1.d
serum subfractions did not alter apo A-I synthesis (data not
shown).
We then examined the effect of uremic serum subfraction on
apo A-I mRNA expression by Northern blot analysis. As shown in
the representative Northern blot (Fig. 4A) and in the quantitative
analysis of all of the data by densitometric scanning (Fig. 4B),
incubation of Hep-G2 cells with uremic serum subfractions de-
creased apo A-I mRNA expression (when compared to gene
expression by normal subject subfractions). Because of the vari-
ability of apo A-I mRNA expression among patients, no signifi-
cant difference was observed at 100 .d of subfraction, although the
optical density appeared lower than seen with control serum
fractions.
The results of the [3H}cholesterol efflux studies (Fig. 5) indicate
Fig. 1. A. Representative Sephadex G-25
chromatograms of semm obtained from a normal
subject (dotted line) and from a uremic patient
(solid line) undergoing peritoneal dialysis. The
Sephadex column was calibrated with standard
molecular weight markers. Fractions (2.4 ml)
were collected and quantitated by measuring
their optical density at 280 nm. Fractions 30 to
60 corresponded to a molecular weight of 500
to 2000 Daltons. The broad peak noted in the
uremic serum was not seen in the normal
serum. B. Sephadex G-25 chromatograms of 2.4
ml fractions obtained from the serum of a
representative normal control subject and from
five patients undergoing peritoneal dialysis(PD). Fractions 30 to 60 are shown. The
increase in optical density at 280 nm seen in
the peritoneal dialysis patients was not seen in
any of the chromatograms obtained with serum
from normal subjects. (See Methods for further
details.)
the ability of the secretory material obtained from Hep-G2 cells
exposed to either normal or uremic subfractions to alter the efflux
of cholesterol from human fibroblasts. The incubation of human
fibroblasts with the conditioned media obtained from the incuba-
tion of Hep-G2 cells with serum subfractions from PD patients
resulted in a 21% decline in the efflux of [3H]cholesterol when
compared to the value obtained with the incubation of the human
fibroblasts with the conditioned medium from normal subjects.
These data suggested that decreased apo A-I by Hep-G2 cells
exposed to uremic subfractions obtained from PD patients was
biologically active in its ability to modulate reverse cholesterol
transport.
Apo B studies
In contrast to the apo A-I data, a significant and time- and
dose-dependent increase in the de novo synthesis of apo B by
Hep-G2 cells was observed in the presence of uremic serum
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Fig. 2. Effect of serum subfractions from normal subjects and uremic
patients on apolipoprotein A-I secretion by Hep-G2 cells. Cells were
incubated at 37°C for 72 hours with either 100 or 200 td of normal or
uremic serum subfractions. At the end of the incubation, culture media
were assayed for apolipoprotein A-I by an enzyme-linked immunoassay
and expressed in terms of total cellular protein. Varying the dose of serum
subfractions from control subjects did not affect the hepatic cell secretion
of apolipoprotein A-I. However, both 100 and 200 1.d of serum subfrac-
tions obtained from peritoneal dialysis patients decreased hepatic apoli-
poprotein A-I secretion in a dose dependent manner. Statistical signifi-
cance was compared to results obtained when control serum subfractions
were compared to those obtained from peritoneal dialysis patients (PD).
subfractions obtained from patients undergoing PD when com-
pared to subfractions from normal subjects (Fig. 6 A, B). The
incubation of Hep-G2 cells with uremic subfractions (200 jil) for
24 hours had no effect on apo B synthesis (Fig. 6A). At 48 hours
uremic subfractions increased apo B synthesis, with a maximal
effect noted at 72 hours of incubation (Fig. 6A). Both 100 and 200
pA of serum subfraction from PD patients resulted in a significant
(42 to 62%) increase in the incorporation of radiolabeled leucine
into newly synthesized apo B when compared to the normal sera
(Fig. 6B). Uremic serum subfractions at 50 pJ concentrations had
no effect on apo B synthesis (data not shown). However, the
incubation of Hep-G2 cells with subfractions obtained from
normal serum had no effect on the incorporation of radiolabeled
leucine into apo B as compared to PBS controls (data not shown).
In comparison, uremic serum subfractions obtained from five HD
patients by the same methods had virtually no effect on the
incorporation of radiolabeled leucine into apo B (data not
shown). Additional experiments were performed to examine the
effect of uremic serum subfractions on apo B secretion into the
culture media. The results indicated that the incubation of uremic
subfractions (200 jil) with Hep-G2 cells increased apo B secretion
into the media as determined by ELISA (apo B secretion: normal
subfraction = 28.1 2.9, uremic subfraction = 40.3 1.2 gig/mg
protein; P = 0.002).
Additional experiments were performed to determine the in-
fluence of uremic subfractions on apo B mRNA expression by
Hep-G2 cells. When compared to the representative normal
serum subfraction (Fig. 7A), uremic serum subfractions obtained
from five of the PD patients markedly increased the apo B mRNA
message. Both 100 and 200 p.l subfractions increased mRNA
expression of apo B by densitometric scanning (Fig. 7B). Al-
Fig. 3. Effect of serum sub fractions from normal subjects and uremic
patients on peritoneal dialysis on the incoiporation of [?HJleucine into
apolipoprotein A-I by Hep-G2 cells. A. Cells were incubated with normal or
uremic serum subfractions (200 j.d) and [3Hjleucine for varying time
periods as indicated. B. Cells were incubated with either 100 or 200 pi of
serum subfractions obtained from normal control subjects (•) orpatients
undergoing peritoneal dialysis () in media containing 5 jCi/ml of[°Hlleucine at 37°C for 72 hours. At the end of the incubation, culture
media were assayed for radiolabeled apolipoprotein A-I by immunopre-
cipitation and expressed as incorporation of radioactivity/mg cell protein.
Varying the dose of serum subfractions from control subjects did not affect
the incorporation of 3H]leucine into apolipoprotein A-I. However, both
100 and 200 /Ll decreased the incorporation of t3Hileucine into apoli-
poprotein A-i. Statistical significance was compared between the results
obtained with control serum subfractions and those obtained from pen-
toneal dialysis patients (PD).
though apo B mRNA expression was increased in Hep-G2 cells
treated with serum subfractions from PD patients, considerable
variability of the apo B message was seen among the three
experiments performed in the various patients.
In additional studies, aliquots of media from de novo synthesis
experiments were analyzed for the incorporation of radiolabeled
leucine into trichloroacetic acid-precipitable proteins to deter-
mine the effect of serum subfractions on total protein synthesis.
The results indicated that neither the uremic nor the normal
serum subfractions altered total protein synthesis by Hep-G2 cells
(data not shown), suggesting that the specific effects of the uremic
serum subfractions were on apolipoprotein synthesis.
To determine whether the active components in the uremic
serum subfractions were heat stable or labile in their ability to
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alter apolipoprotein synthesis, uremic serum subfractions were
incubated at 100°C for 30 minutes prior to their use in Hep-G2
cell studies to measure apo A-I and B synthesis. Heat treatment of
uremic subfractions did not alter either apo A-I or B synthesis
(data not shown).
Discussion
Fig. 4. A. Northern blot analysis showing the
effect of serum subfractions from three normal
subjects and five uremic patients on the steady-
state mRNA expression of apolipoprotein A-I
mRNA by I-Iep-G2 cells. Cells were incubated at
37°C for 72 hours with either normal or uremic
serum subfractions (200 pJ), washed with PBS
and total cellular RNA isolated,
electrophoresed, and transferred onto nylon
membranes as described in the Methods
section. Northern blots were hybridized with
[32P]-labeled human eDNA probe for
apolipoprotein A-I and then rehybridized with a
cDNA probe for GAPDH. Autoradiographs
were developed by exposing the blot to X-ray
film. B. Quantitative analysis of the effect of
serum subfractions obtained from control
subjects (•) and from patients undergoing
peritoneal dialysis () on the steady-state
hepatic cell mRNA expression of
apolipoprotein A-I. Data for both 100 and 200
j.rl of serum subfractions are shown. After
developing the Northern blots, quantitation of
apolipoprotein A-I mRNA signals on the
autoradiographs was performed using a LKB-
Ultra scan laser densitometer and results were
normalized to the respective GAPDH signal.
Data are expressed as the optical density of the
signal when normalized by the GAPDH
message. No differences in apolipoprotein A-I
gene expression were noted when using either
concentration of normal serum subfraction.
However, serum subfractions obtained from
uremic patients undergoing peritoneal dialysis(PD) showed decreased apolipoprotein A-I
mRNA message although this decreased
reached statistical significance only with the 200
ILl dose.
Serum lipid and lipoprotein abnormalities are common meta-
bolic disturbances seen in patients with chronic renal disease. In
addition to serum lipid and lipoprotein abnormalities and other
metabolic disturbances seen in patients with chronic renal disease,
the type of dialytic therapy used in these patients appears to be
able to influence their lipid profile. Previous studies have shown
that PD patients have higher serum total and LDL-C levels
associated with an increase in apo B and apo (a) levels than
patients receiving HD. In addition, both treatment modalities are
associated with decreased serum HDL-C and apo A-I. Based on
these observations, it has been suggested that PD patients are at
a greater risk of atherosclerotic cardiovascular disease than
patients undergoing HD [5—71. The PD patients in the present
study has varying values of serum apo A-I and all had elevated
serum apo B levels.
The results of our data confirm that uremic serum subfractions
obtained from PD patients inhibited the protein secretion and
synthesis and the mRNA expression of apo A-I by human
hepatoma cells. Since uremic subfractions from PD patients
Fig. 5. Effect of apolipoprotein A -I particles obtained from the incubation of
Hep-G2 cells with either normal serum suhfractions or uremic serum
,subfractions obtained from peritoneal dialysis patients on the elf lux of
[3Hjcholesterol from human fibrohlast.s'. Human fibroblasts were preloaded
with [3Hlcholesterol and cxposed to conditioned media obtained by
incubating Hep-G2 cells with normal or uremic serum subfractions for 20
hours in a humidified incubator. No differences in [3Hlcholesterol efflux
were seen with the two concentrations of normal serum subfractions.
However, uremic serum subfractions obtained from patients undergoing
peritoneal dialysis (PD) decreased [3Hjcholesterol efflux significantly at
the two doses used when compared to the normal serum subfraction data.
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Fig. 6. Effect of serum suhfractions from normal subjects and uremic
patients undeigoing peritoneal dialysis on the incorporation of [3J-I]leucine
into apolipoprotein B in Hep-G2 cells. (A) Cells were incubated with normal
(U) or uremic (B) serum subtractions (200 rl) and [3H]leucine for varying
time periods as indicated. (B) Cells were incubated with either 100 or 200
pi of serum subfractions obtained from normal control subjects or patients
undergoing peritoneal dialysis (PD) in media containing 5 jLCi/ml of
[3H]leucine at 37°C for 72 hours. At the end of the incubation, culture
media were assayed for radiolabcled apolipoprotein B by immunoprecipi-
tation and expressed as the incorporation of radioactivity/mg cell protein.
Varying the dose of serum subtractions from control subjects did not affect
the incorporation of [3Hlleucine into apolipoprotein B. However, both
100 and 200 jd of serum subfractions obtained from PD patients increased
the incorporation of [3H]leucine into apolipoprotein B. Statistical signif-
icance was compared between results obtained from control serum
suhfractions and those obtained from PD patients.
inhibited apo A-I mRNA expression, these data suggested that
some component present in uremic serum subfraction having a
molecular weight between 500 and 2000 Daltons has the capacity
to inhibit the protein synthesis and mRNA expression of apo A-I.
The functional impact of reduced apo A-I was examined in the
[3H]cholesterol efflux studies involving human fibroblasts. As
seen, the efflux of [3H]cholesterol from fibroblasts was reduced
only during incubation of fibroblasts with the Hep G-2 cell-
conditioned media obtained from PD patients and not control
subjects, a finding suggesting that apo A-I secreted into the media
was physiologically active in altering reverse cholesterol transport
pathways. These in vitro observations may partly explain the
decreased rates of apo A-I synthesis observed in patients with
uremia [21]. Additionally, an increased fractional catabolic rate
for apo A-I in uremic patients has been observed [21] and may
also contribute to decreased HDL-C and apo A-I concentrations
seen in these patients. Furthermore, the hypertriglyceridemia
seen in uremic patients may accelerate the clearance of apo A-I
[22, 23] and also lead to an increased exchange of cholesterol from
HDL to VLDL, thus resulting in the formation of a cholesterol-
enriched VLDL particles that have also been proposed to be
associated with accelerated atherosclerosis [24]. Since the apo A-I
mass accumulated in the media was a combination of secretion
and removal, the re-uptake of apo A-I by cells may also contribute
to the regulatory mechanisms of apo A-I accumulation. In previ-
ous studies [9], we have shown that the intracellular distribution of
apo A-I in control and uremic subfraction-treated Hep-G2 cells
was 23% of the apo A-I mass in the media. Because of comparable
intracellular accumulation of apo A-I in both control and uremic
serum subfraction exposed cells, it would be unlikely that a
component of the uremic serum affected the re-uptake or removal
of apo A-I by Hep-G2 cells in our studies. In addition, lowered
activities of lipoprotein metabolizing enzymes including lipopro-
tein lipase, hepatic triglyceride lipase and lecithin:cholesterol
acyltransferase [25] may further contribute to the lipoprotein
abnormalities seen in uremic patients [25].
Studies involving apo B synthesis by Hep-G2 cells showed a
significant increase in de novo apo B protein synthesis by the
human hepatoma cells in presence of uremic sera subfractions
from PD patients by using a [3H]leucine incorporation technique
(Fig. 6). Furthermore, Northern blot analysis showed a 3.5-fold
rise in the apo B mRNA expression under similar experimental
conditions. In contrast, there was no change observed in apo B
synthesis by Hep-G2 cells in studies using the serum subfractions
from either control subjects or HD patients. These observations in
part may explain relatively greater serum LDL-C values observed
in the patients receiving PD compared to those maintained by
HD. However, these in vitro data are not totally consistent with
the generally accepted premise that the delayed clearance, rather
than the increased production of LDL, is a major mechanism to
explain the hyperlipidemia seen in uremic patients [26]. These
differences between in vitro and in vivo systems may be multifac-
tonal and may include an effect of humoral mechanisms and/or
factors dependent on underlying diseases.
The potential mechanisms that may regulate the metabolism of
apo A-I and apo B by the hepatocytes in dialysis patients remain
to be fully elucidated. The putative toxins that accumulate in
uremic sera may affect metabolism of apoproteins. In this regard,
the serum subfractions from both hemodialysis and PD patients
appear to have similar effects with respect to apo A-I synthesis,
secretion and mRNA expression by the human hepatoma cell line.
Since peritoneal membrane is permeable to macromolecules such
as albumin and immunoglobulins, peritoneal removal rates of
apoproteins have been measured. The reported peritoneal apo
A-I losses (about 300 mg/day) [27] probably contributes minimally
to the low serum apo A-I values, since these losses constitutes less
than 10% of the estimated apo A-I pool size (approximately 62
mg/kg) [21].
Because of the lack of information on the identification and
characterization of specific uremic factors accumulated in HD and
PD patients, the differences in the atherogenic apo B synthesis
between the two patient groups cannot be explained by the
possibility of enhanced PD clearances of one or more circulating
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Fig. 7. 4 Northern blot analysis showing the
effect of serum subfractions from one normal
subject (representative of 5 subjects) and five
uremic patients on steady-state mRNA expression
of apolipoprotein B mRNA by Hep-G2 cells.
Cells were incubated at 37°C for 72 hours with
normal or uremic serum subfractions (200 xl),
washed with PBS and total cellular RNA
isolated, electrophoresed, and transferred onto
nylon membranes as described in the Methods
section. Northern blots were hybridized with
[12P1-labeled human cDNA probe for
apolipoprotein B and then rehybridized with
eDNA probe for GAPDH. Autoradiographs
were developed by exposing blots to X-ray film.
B. Quantitative analysis of the effect of serum
subfractions obtained from control subjects and
from uremic patients undergoing peritoneal
dialysis (PD) on steady-state Hep-G2 cell
mRNA expression of apolipoprotein B. Data
for both 100 and 200 td of serum subfractions
are shown. After developing the Northern blots,
quantitation of apolipoprotein B mRNA signals
on the autoradiographs was performed using a
LKB-Ultra scan laser densitometer and results
were normalized to the respective GAPDH
signal. Data are expressed as the optical density
of the signal when normalized by the GAPDH
message. No differences in apolipoprotein B
gene expression were noted when using either
concentration of the normal serum subfraction.
However, serum subfractions obtained from
uremic patients undergoing peritoneal dialysis
increased the apolipoprotein B mRNA
message.
factors. Apo B synthesis by these human hepatocytes was mark-
edly increased by serum subfractions from PD patients. However,
no change was seen when experiments using similar serum
subfractions from HD patients were performed. Since the in-
creased accumulation of plasma apo B is a strong predictor for
atherosclerotic cardiovascular disease, a major effort has been
directed toward identifying the regulatory factors and related
intracellular processes that govern apo B synthesis and secretion.
In this regard, investigators have reported that a significant
amount of apo B synthesized by hepatocytes is not secreted into
the plasma but rather degraded intracellularly [28, 291. Further-
more, recent studies have indicated that the translocation of apo
B across the endoplasmic reticulum rather than degradation
regulates the intracellular fate of de novo synthesized apo B [30].
This degradation has also been observed in Hep-G2 cells [31, 321,
and may play an important role in the overall regulation of hepatic
cell apo B secretion. For example, treatment of Hep-G2 cells with
oleate or glucocorticoids increased apo B secretion by decreasing
apo B degradation [32, 33]. Conversely, in rat hepatocytes, insulin
decreased the secretion of apo B through the stimulation of
intracellular degradation [29]. Recently it was shown that the
secretion of apo B by Hep-G2 cells was suppressed by bovine
serum albumin, and that this phenomenon was mediated by
increased intracellular degradation of apo B [34]. Additionally,
the effect of oleate to inhibit apo B degradation was enhanced by
binding to low concentrations of albumin [34]. Based on these
observations, it can be suggested that hypoalbuminemic condi-
tions that may occur in patients with the nephrotic syndrome and
those receiving PD therapy may inhibit the normal posttransla-
tional hepatic apo B degradation leading to increased apo B
containing lipoprotein secretion into the plasma. Although he-
patic apo B gene expression is generally not altered by various
endogenous or exogenous factors, we have shown in this study
that the uremic subfractions isolated from PD patients signifi-
cantly increased steady-state mRNA expression of apo B in
Hep-G2 cells. Whereas, previous studies suggested post-transla-
tional apo B degradation as a major regulatory mechanism, recent
studies indicated that the alterations in apo B secretion by amino
acids and 25-hydroxycholesterol in Hep-G2 cells were regulated
by influencing apo B mRNA expression [35, 36]. Furthermore, we
have observed an inverse correlation between serum albumin and
apo (a) levels in patients receiving PD [7]. Hence, the putative
factors present in the plasma of PD and hypoalbuminemic
patients may subject these individuals to an additional athero-
genie risk through increased apo B synthesis and decreased
intracellular degradation, leading to a marked increase in apo B
secretion. In this regard, elevated levels of free fatty acids have
been shown to regulate apo B secretion by hepatocytes [32].
Finally, although it is possible that the carbohydrate loading from
the dialysate in PD patients could lead to hypertriglyceridemia, in
vitro studies in the Hep G-2 cells have reported no effect of the
ambient glucose concentration on apo B secretion [37].
In conclusion, our studies provide additional mechanisms for
lipoprotein abnormalities in dialysis patients. Altered hepatic
Shah et al. Effect of PD on hepatic apo A-I and B 2087
synthesis and secretion of apo A-I and B may contribute to the
atherogenic lipoprotein profile in PD patients, and may in part
explain the relative increase in the cardiovascular morbidity
reported in this patient population. Further studies are needed to
more completely understand the molecular mechanisms of these
abnormalities in response to specific factor(s) present in uremic
plasma.
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